Teva Canada, a major pharmaceutical company, has announced a voluntary recall of some of its Teva-Pregabalin 150 mg capsules. The decision to recall these capsules was based on findings from routine testing, which raised alerts over possible contamination with sertraline, a medication typically used to treat depression and anxiety disorders. The implications of this recall are significant as Pregabalin is prescribed for conditions such as neuropathic pain and seizures.
In the interest of consumer safety, Teva Canada is advising anyone who may have purchased the affected capsules to review their supplies and consult with their healthcare provider if they have concerns regarding the contamination. The company has outlined steps for the return of the recalled products and has emphasized its commitment to maintaining high manufacturing standards and ensuring the safety of its medications.
This recall represents Teva Canada's proactive approach to addressing potential health risks associated with its products. As patients rely on medications like Pregabalin for their health, the company encourages ongoing communication about the importance of product safety and vigilance in checking for recalls.
Analyzed Canadian Outlets (1)
1 headline